Cargando…
Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data”
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267305/ https://www.ncbi.nlm.nih.gov/pubmed/32348544 http://dx.doi.org/10.1002/cpt.1873 |
| _version_ | 1783541439778521088 |
|---|---|
| author | Garcia‐Cremades, Maria Solans, Belen P. Hughes, Emma Ernest, Jacqueline P. Wallender, Erika Savic, Radojka M. |
| author_facet | Garcia‐Cremades, Maria Solans, Belen P. Hughes, Emma Ernest, Jacqueline P. Wallender, Erika Savic, Radojka M. |
| author_sort | Garcia‐Cremades, Maria |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7267305 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72673052020-06-03 Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” Garcia‐Cremades, Maria Solans, Belen P. Hughes, Emma Ernest, Jacqueline P. Wallender, Erika Savic, Radojka M. Clin Pharmacol Ther Perspectives John Wiley and Sons Inc. 2020-05-20 2020-08 /pmc/articles/PMC7267305/ /pubmed/32348544 http://dx.doi.org/10.1002/cpt.1873 Text en © 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Perspectives Garcia‐Cremades, Maria Solans, Belen P. Hughes, Emma Ernest, Jacqueline P. Wallender, Erika Savic, Radojka M. Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” |
| title | Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” |
| title_full | Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” |
| title_fullStr | Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” |
| title_full_unstemmed | Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” |
| title_short | Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” |
| title_sort | response to “quantitative clinical pharmacology input to sars‐cov‐2 therapeutics should be based on robust data” |
| topic | Perspectives |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267305/ https://www.ncbi.nlm.nih.gov/pubmed/32348544 http://dx.doi.org/10.1002/cpt.1873 |
| work_keys_str_mv | AT garciacremadesmaria responsetoquantitativeclinicalpharmacologyinputtosarscov2therapeuticsshouldbebasedonrobustdata AT solansbelenp responsetoquantitativeclinicalpharmacologyinputtosarscov2therapeuticsshouldbebasedonrobustdata AT hughesemma responsetoquantitativeclinicalpharmacologyinputtosarscov2therapeuticsshouldbebasedonrobustdata AT ernestjacquelinep responsetoquantitativeclinicalpharmacologyinputtosarscov2therapeuticsshouldbebasedonrobustdata AT wallendererika responsetoquantitativeclinicalpharmacologyinputtosarscov2therapeuticsshouldbebasedonrobustdata AT savicradojkam responsetoquantitativeclinicalpharmacologyinputtosarscov2therapeuticsshouldbebasedonrobustdata |